We are analyzing https://link.springer.com/article/10.1007/s11094-022-02599-x.

Title:
Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects | Pharmaceutical Chemistry Journal
Description:
Cyclin-dependent kinases 4 and 6 (CDK4/6) are the core part of the cell cycle control machinery, which bind to cyclin D to regulate cell G1-S cycle conversion. CDK4/6 inhibitors are currently used to treat HR-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC), and the US FDA has approved three CDK4/6 inhibitors as palbociclib, ribociclib and abemaciclib. In order to provide better reference for the development of CDK4/6 inhibitors, this review summarized the research progress of CDK4/6 inhibitors. Potential drug resistance mechanism and combining medication strategies have been reviewed to reduce the occurrence of drug resistance. CDK4/6 inhibitors combined with fulvestrant or anastrozole showed positive efficacy in the treatment of breast cancer. Reducing the side effects is the crux of the development of CDK4/6 inhibitors in the future.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

pubmed, article, google, scholar, cas, cancer, central, res, inhibitors, breast, cdk, cell, clin, research, drug, rev, ther, privacy, cookies, content, journal, cyclindependent, oncol, mol, author, publish, search, kinase, treat, fda, approved, resistance, access, nat, patent, data, information, log, therapy, progress, xiandeng, discover, knudsen, nature, harvey, med, chem, liu, martin, lorusso,

Topics {✒️}

cyclin-dependent kinase 4 month download article/chapter metastatic breast cancer breast cancer therapy article google scholar drug resistance breast cancer res treat hr-positive privacy choices/manage cookies hr+/her2 related subjects approved drug files full article pdf providing financial support journal finder publish cdk4/6 inhibitors combined breast cancer european economic area combining medication strategies traditional chinese medicine conditions privacy policy regulate cell g1 accepting optional cookies article li check access instant access article log her2-negative author information authors research progress article cite treat options oncol journal publish palbociclib ribociclib abemaciclib xiandeng li cdk4/6 inhibitors cancer cell cyclin privacy policy cancer res personal data cancer treat books a genes cancer cancer ther cancer discov optional cookies manage preferences

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
         description:Cyclin-dependent kinases 4 and 6 (CDK4/6) are the core part of the cell cycle control machinery, which bind to cyclin D to regulate cell G1-S cycle conversion. CDK4/6 inhibitors are currently used to treat HR-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC), and the US FDA has approved three CDK4/6 inhibitors as palbociclib, ribociclib and abemaciclib. In order to provide better reference for the development of CDK4/6 inhibitors, this review summarized the research progress of CDK4/6 inhibitors. Potential drug resistance mechanism and combining medication strategies have been reviewed to reduce the occurrence of drug resistance. CDK4/6 inhibitors combined with fulvestrant or anastrozole showed positive efficacy in the treatment of breast cancer. Reducing the side effects is the crux of the development of CDK4/6 inhibitors in the future.
         datePublished:2022-03-30T00:00:00Z
         dateModified:2022-03-30T00:00:00Z
         pageStart:71
         pageEnd:77
         sameAs:https://doi.org/10.1007/s11094-022-02599-x
         keywords:
            CDK4/6 inhibitors
            metastatic breast cancer
            HR+/Her2-
            palbociclib
            ribociclib
            abemaciclib
            Pharmacy
            Pharmacology/Toxicology
            Organic Chemistry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch3_HTML.jpg
         isPartOf:
            name:Pharmaceutical Chemistry Journal
            issn:
               1573-9031
               0091-150X
            volumeNumber:56
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Xiandeng Li
               affiliation:
                     name:Chengdu University of Traditional Chinese Medicine
                     address:
                        name:College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Cyclin-Dependent Kinase 4 and 6 Inhibitors as Breast Cancer Therapy: Research Progress and Prospects
      description:Cyclin-dependent kinases 4 and 6 (CDK4/6) are the core part of the cell cycle control machinery, which bind to cyclin D to regulate cell G1-S cycle conversion. CDK4/6 inhibitors are currently used to treat HR-positive and HER2-negative (HR+/HER2-) metastatic breast cancer (MBC), and the US FDA has approved three CDK4/6 inhibitors as palbociclib, ribociclib and abemaciclib. In order to provide better reference for the development of CDK4/6 inhibitors, this review summarized the research progress of CDK4/6 inhibitors. Potential drug resistance mechanism and combining medication strategies have been reviewed to reduce the occurrence of drug resistance. CDK4/6 inhibitors combined with fulvestrant or anastrozole showed positive efficacy in the treatment of breast cancer. Reducing the side effects is the crux of the development of CDK4/6 inhibitors in the future.
      datePublished:2022-03-30T00:00:00Z
      dateModified:2022-03-30T00:00:00Z
      pageStart:71
      pageEnd:77
      sameAs:https://doi.org/10.1007/s11094-022-02599-x
      keywords:
         CDK4/6 inhibitors
         metastatic breast cancer
         HR+/Her2-
         palbociclib
         ribociclib
         abemaciclib
         Pharmacy
         Pharmacology/Toxicology
         Organic Chemistry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11094-022-02599-x/MediaObjects/11094_2022_2599_Sch3_HTML.jpg
      isPartOf:
         name:Pharmaceutical Chemistry Journal
         issn:
            1573-9031
            0091-150X
         volumeNumber:56
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Xiandeng Li
            affiliation:
                  name:Chengdu University of Traditional Chinese Medicine
                  address:
                     name:College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Pharmaceutical Chemistry Journal
      issn:
         1573-9031
         0091-150X
      volumeNumber:56
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Chengdu University of Traditional Chinese Medicine
      address:
         name:College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Xiandeng Li
      affiliation:
            name:Chengdu University of Traditional Chinese Medicine
            address:
               name:College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

Social Networks {👍}(1)

https://link.springer.com/article/10.1007/s11094-022-02599-x/mailto:[email protected]

External Links {🔗}(176)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4s.

LINK . SPRINGER . COM {}